NCT05156034 is a Phase 1 clinical trial of SRK-001 in Healthy Participants, sponsored by Sarkana Pharma Inc.

Who is sponsoring NCT05156034?

NCT05156034 is sponsored by Sarkana Pharma Inc.

What drugs are being tested in NCT05156034?

Interventions in NCT05156034: SRK-001, Placebo.

What condition does NCT05156034 study?

NCT05156034 studies Healthy Participants.

Is NCT05156034 still recruiting?

NCT05156034 is currently terminated. Last updated 13 March 2023.

Last reviewed 2023-03-13 · How we verify

NCT05156034

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SRK-001 in Healthy Participants

Terminated Phase 1 Last updated 13 March 2023

What this trial tests

Phase 1 trial testing SRK-001 in Healthy Participants in 16 participants. Terminated before completion.

Timeline

21 December 2021

Primary endpoint
5 September 2022

5 September 2022

Quick facts

Lead sponsor	Sarkana Pharma Inc
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	21 December 2021
Primary completion	5 September 2022
Estimated completion	5 September 2022
Sites	1 location across Netherlands

Drugs / interventions tested

SRK-001 — full drug profile →
Placebo

Conditions studied

Healthy Participants — all drugs for Healthy Participants →

Sponsor

Sarkana Pharma Inc — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Participants. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate safety, tolerability, and pharmacokinetics (PK) of SRK-001 in Healthy Participants.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Targeting γc family cytokines with biologics: current status and future prospects.
Bick F, Blanchetot C, Lambrecht BN, Schuijs MJ. · · 2025 · cited 5× · PMID 39967341 · DOI 10.1080/19420862.2025.2468312

Verify or expand the search:

Other recruiting trials for Healthy Participants

Currently open trials in the same condition.

NCT07469085 — A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Partici · Phase 1 · recruiting
NCT07503990 — Effects of Food Intake Sequence on Substrate Utilisation and Endurance Performance · NA · recruiting
NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
NCT07511205 — A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participa · Phase 1 · recruiting
NCT07448155 — A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INCA033989 Following Subcutaneous or Intravenous A · Phase 1 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05156034 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sarkana Pharma Inc
Last refreshed: 13 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05156034.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing